Literature DB >> 21559550

A new perspective on optimal care for patients with COPD.

Dirkje Postma1, Antonio Anzueto, Peter Calverley, Christine Jenkins, Barry J Make, Frank C Sciurba, Thomas Similowski, Thys van der Molen, Göran Eriksson.   

Abstract

Worldwide, clinicians face the task of providing millions of patients with the best possible treatment and management of COPD. Currently, management primarily involves short-term 'here-and-now' goals, targeting immediate patient benefit. However, although there is considerable knowledge available to assist clinicians in minimising the current impact of COPD on patients, relatively little is known about which dominant factors predict future risks. These predictors may vary for different outcomes, such as exacerbations, mortality, co-morbidities, and the long-term consequences of COPD. We propose a new paradigm to achieve 'optimal COPD care' based on the concept that here-and-now goals should be integrated with goals to improve long-term outcomes and reduce future risks. Whilst knowledge on risk factors for poorer outcomes in COPD is growing and some data exist on positive effects of pharmacological interventions, information on defining the benefits of all commonly used interventions for reducing the risk of various future disease outcomes is still scarce. Greater insight is needed into the relationships between the two pillars of optimal COPD care: 'best current control' and 'future risk reduction'. This broader approach to disease management should result in improved care for every COPD patient now and into the future.

Entities:  

Mesh:

Year:  2011        PMID: 21559550      PMCID: PMC6549820          DOI: 10.4104/pcrj.2011.00041

Source DB:  PubMed          Journal:  Prim Care Respir J        ISSN: 1471-4418


  12 in total

Review 1.  Budesonide/formoterol Turbuhaler®: a review of its use in chronic obstructive pulmonary disease.

Authors:  Lesley J Scott
Journal:  Drugs       Date:  2012-02-12       Impact factor: 9.546

2.  [Spanish COPD Guidelines (GesEPOC): Pharmacological treatment of stable COPD].

Authors:  Marc Miravitlles; Juan José Soler-Cataluña; Myriam Calle; Jesús Molina; Pere Almagro; José Antonio Quintano; Juan Antonio Riesco; Juan Antonio Trigueros; Pascual Piñera; Adolfo Simón; José Luis López-Campos; Joan B Soriano; Julio Ancochea
Journal:  Aten Primaria       Date:  2012-06-15       Impact factor: 1.137

3.  A score to predict short-term risk of COPD exacerbations (SCOPEX).

Authors:  Barry J Make; Göran Eriksson; Peter M Calverley; Christine R Jenkins; Dirkje S Postma; Stefan Peterson; Ollie Östlund; Antonio Anzueto
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-01-27

4.  Reliever salbutamol use as a measure of exacerbation risk in chronic obstructive pulmonary disease.

Authors:  Christine R Jenkins; Dirkje S Postma; Antonio R Anzueto; Barry J Make; Stefan Peterson; Göran Eriksson; Peter M Calverley
Journal:  BMC Pulm Med       Date:  2015-08-21       Impact factor: 3.317

5.  Identifying cases of undiagnosed, clinically significant COPD in primary care: qualitative insight from patients in the target population.

Authors:  Nancy K Leidy; Katherine Kim; Elizabeth D Bacci; Barbara P Yawn; David M Mannino; Byron M Thomashow; R Graham Barr; Stephen I Rennard; Julia F Houfek; Meilan K Han; Catherine A Meldrum; Barry J Make; Russ P Bowler; Anna W Steenrod; Lindsey T Murray; John W Walsh; Fernando Martinez
Journal:  NPJ Prim Care Respir Med       Date:  2015-04-16       Impact factor: 2.871

6.  Roflumilast, a phosphodiesterase-4 inhibitor, induces phagocytic activity in Greek COPD patients.

Authors:  Konstantinos Porpodis; Kalliopi Domvri; Paul Zarogoulidis; Dimitrios Petridis; Katerina Tsirgogianni; Antonis Papaioannou; Olga Hatzizisi; Ioannis Kioumis; Alexandra Liaka; Violeta Kikidaki; Sofia Lampaki; John Organtzis; Konstantinos Zarogoulidis
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-06-15

7.  Living in negotiation: patients' experiences of being in the diagnostic process of COPD.

Authors:  Sari Lindgren; Sissel Lisa Storli; Lena Wiklund-Gustin
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2014-05-06

8.  Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? The REACT study protocol.

Authors:  Peter M A Calverley; Fernando J Martinez; Leonardo M Fabbri; Udo-Michael Goehring; Klaus F Rabe
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2012-06-20

9.  Day-to-day measurement of patient-reported outcomes in exacerbations of chronic obstructive pulmonary disease.

Authors:  Jan Willem H Kocks; Jan Willem K van den Berg; Huib A M Kerstjens; Steven M Uil; Judith M Vonk; Ynze P de Jong; Ioanna G Tsiligianni; Thys van der Molen
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2013-06-06

Review 10.  COPD management: role of symptom assessment in routine clinical practice.

Authors:  Thys van der Molen; Marc Miravitlles; Janwillem W H Kocks
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2013-10-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.